# Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review)

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2013, Issue 10

http://www.thecochranelibrary.com



Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.




#### TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	3
OBJECTIVES	4
METHODS	4
RESULTS	9
Figure 1	10
Figure 2	13
Figure 3	14
Figure 4	16
Figure 5	18
Figure 6	20
DISCUSSION	21
AUTHORS' CONCLUSIONS	24
ACKNOWLEDGEMENTS	24
REFERENCES	25
CHARACTERISTICS OF STUDIES	28
DATA AND ANALYSES	43
Analysis 1.1. Comparison 1 Valproate versus placebo, Outcome 1 Study withdrawal due to episode of mood disorder.	46
Analysis 1.2. Comparison 1 Valproate versus placebo, Outcome 2 Participant withdrawal from treatment-any cause.	47
Analysis 1.3. Comparison 1 Valproate versus placebo, Outcome 3 Participant withdrawal from treatment due to intolerance	
or non-compliance	47
Analysis 1.4. Comparison 1 Valproate versus placebo, Outcome 4 Adverse events.	48
Analysis 2.1. Comparison 2 Valproate versus lithium, Outcome 1 Study withdrawal due to episode of mood disorder.	49
Analysis 2.2. Comparison 2 Valproate versus lithium, Outcome 2 Number of hospital admissions	50
Analysis 2.3. Comparison 2 Valproate versus lithium, Outcome 3 New drug treatment for mood episode	51
Analysis 2.4. Comparison 2 Valproate versus lithium, Outcome 4 Time to relapse (days)	51
Analysis 2.5. Comparison 2 Valproate versus lithium, Outcome 5 Participant withdrawal from treatment-any cause.	52
Analysis 2.6. Comparison 2 Valproate versus lithium, Outcome 6 Participant withdrawal from treatment due to intolerance	
or non-compliance	53
Analysis 2.7. Comparison 2 Valproate versus lithium, Outcome 7 Adverse events.	54
Analysis 2.8. Comparison 2 Valproate versus lithium, Outcome 8 GAF-number of participants not responding at 24	,
months	55
Analysis 2.9. Comparison 2 Valproate versus lithium, Outcome 9 Quality of life-number of participants not responding at	,
24 months	56
Analysis 2.10. Comparison 2 Valproate versus lithium, Outcome 10 DSH-number of participants with at least one episode	,
of deliberate self-harm	56
Analysis 2.11. Comparison 2 Valproate versus lithium, Outcome 11 Death.	57
Analysis 3.1. Comparison 3 Valproate versus olanzapine, Outcome 1 Study withdrawal due to episode of mood disorder.	57
Analysis 3.2. Comparison 3 Valproate versus olanzapine, Outcome 2 Participant withdrawal from treatment-any cause.	58
Analysis 3.3. Comparison 3 Valproate versus olanzapine, Outcome 3 Participant withdrawal from treatment due to	)(
intolerance or non-compliance	58
Analysis 4.1. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 1 Study withdrawal due to episode of	)(
mood disorder	59
Analysis 4.2. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 2 Number of hospital admissions.	59
Analysis 4.3. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 3 New drug treatment for mood	))
episode	60
Analysis 4.4. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 4 Participant withdrawal from treatment-	00
any cause	60
uii, cuide	00

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Analysis 4.5. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 5 Participant withdrawal from treatment	
due to intolerance or non-compliance.	61
Analysis 4.6. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 6 Serious adverse events	61
Analysis 4.7. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 7 GAF-number of participants not responding at 24 months.	62
Analysis 4.8. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 8 Quality of life-number of participants not responding at 24 months.	62
Analysis 4.9. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 9 DSH-number of participants with at	
least one episode of deliberate self-harm.	63
Analysis 4.10. Comparison 4 Valproate plus lithium versus lithium alone, Outcome 10 Death	63
Analysis 5.1. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 1 Study withdrawal due to episode of mood disorder.	64
Analysis 5.2. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 2 Number of hospital admissions.	64
Analysis 5.3. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 3 New drug treatment for mood	
episode	65
Analysis 5.4. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 4 Participant withdrawal from	
treatment-any cause.	65
Analysis 5.5. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 5 Participant withdrawal from	
treatment due to intolerance or non-compliance	66
Analysis 5.6. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 6 Serious adverse events	66
Analysis 5.7. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 7 GAF-number of participants not	
responding at 24 months	67
Analysis 5.8. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 8 Quality of life-number of participants	i
not responding at 24 months.	67
Analysis 5.9. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 9 DSH-number of participants with a	:
least one episode of deliberate self-harm.	68
Analysis 5.10. Comparison 5 Valproate plus lithium versus valproate alone, Outcome 10 Death	68
ADDITIONAL TABLES	68
WHAT'S NEW	71
HISTORY	71
CONTRIBUTIONS OF AUTHORS	71
DECLARATIONS OF INTEREST	71
SOURCES OF SUPPORT	72
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	72
INDEX TERMS	72





[Intervention Review]

## Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder

Andrea Cipriani<sup>1</sup>, Keith Reid<sup>2</sup>, Allan H Young<sup>3</sup>, Karine Macritchie<sup>4</sup>, John Geddes<sup>5</sup>

<sup>1</sup>Department of Psychiatry, University of Oxford, Oxford, UK. <sup>2</sup>Bamburgh Clinic, Northumberland Tyne and Wear NHS Foundation Trust, Newcastle, UK. <sup>3</sup>Division of Brain Sciences, Centre for Mental Health, Imperial College London, London, UK. <sup>4</sup>Division of Psychiatry, University of Edinburgh, Edinburgh, UK. <sup>5</sup>Department of Psychiatry, University of Oxford/Warneford Hospital, Oxford, UK

Contact address: John Geddes, Department of Psychiatry, University of Oxford/Warneford Hospital, Oxford, OX3 7JX, UK. john.geddes@psych.ox.ac.uk.

Editorial group: Cochrane Depression, Anxiety and Neurosis Group.

**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 10, 2013. **Review content assessed as up-to-date:** 11 January 2013.

Citation: Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *Cochrane Database of Systematic Reviews* 2013, Issue 10. Art. No.: CD003196. DOI: 10.1002/14651858.CD003196.pub2.

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#### ABSTRACT

#### Background

Bipolar disorder is a recurrent illness that is amongst the top 30 causes of disability worldwide and is associated with significant healthcare costs. In the past, emphasis was placed solely on the treatment of acute episodes of bipolar disorder; recently, the importance of episode prevention and of minimisation of iatrogenicity has been recognised. For many years, lithium was the only mood stabiliser in common use, and it remains an agent of first choice in the preventative treatment of bipolar disorder. However, an estimated 20% to 40% of patients may not respond adequately to lithium. Valproate is an anticonvulsant drug that has been shown to be effective in acute mania and is frequently used in maintenance treatment of bipolar disorder. When the acceptability of long-term treatment is considered, together with efficacy, the adverse event profile of a medication is also important. This is an update of a Cochrane review first published in 2001 and last updated in 2009.

#### **Objectives**

- 1. To determine the efficacy of valproate continuation and maintenance treatment:
- a) in preventing or attenuating manic, depressive and mixed episodes of bipolar disorder;
- b) in preventing or attenuating episodes of bipolar disorder in patients with rapid cycling disorder; and
- c) in improving patients' general health and social functioning, as measured by global clinical impression, employment and marital stability.
- 2. To review the acceptability to patients of long-term valproate treatment, as measured by numbers of dropouts and reasons for dropping out, by compliance and by reference to patients' expressed views regarding treatment.
- 3. To investigate the adverse effects of valproate treatment (including general prevalence of side effects) and overall mortality rates.

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



#### Search methods

Search of the Cochrane Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register (CC-DANCTR) (to January 2013), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years), EMBASE, (1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). No language restrictions were applied. Reference lists of relevant papers and previous systematic reviews were handsearched. Pharmaceutical companies marketing valproate and experts in this field were contacted for supplemental data.

#### Selection criteria

Randomised controlled trials allocating participants with bipolar disorder to long-term treatment with valproate or any other mood stabiliser, or antipsychotic drugs, or placebo. Maintenance treatment was defined as treatment instituted specifically or mainly to prevent further episodes of illness.

#### Data collection and analysis

Three review authors independently extracted data. A double-entry procedure was employed by two review authors. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. For dichotomous data, risk ratios were calculated with 95% confidence intervals (CIs). For statistically significant results, we calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH). For continuous data, mean differences (MDs) or standardised mean differences (SMDs) were calculated along with 95% CIs. MDs were used when the same scale was used to measure an outcome; SMDs were employed when different scales were used to measure the same outcome. The primary analysis used a fixed-effect model. Binary outcomes were calculated on a strict intention-to-treat (ITT) basis; dropouts were included in this analysis. When data were missing and the method of "last observation carried forward" (LOCF) had been used to do an ITT analysis, then the LOCF data were used.

#### Main results

Six randomised controlled trials (overall 876 participants) lasting 6 to 24 months were included. Two studies (overall 312 participants) compared valproate with placebo, four studies (overall 618 participants) valproate with lithium, one study (overall 23 participants) valproate with olanzapine and one study (overall 220 participants) valproate with the combination of valproate plus lithium. In terms of study quality, most studies reported the methods used to generate random sequence; however, only one study reported enough details on allocation concealment. Four of six included studies described their design as "double blind", but only two trials reported full details about blinding. Valproate was more effective than placebo in preventing study withdrawal due to any mood episode (RR 0.68, 95% CI 0.49 to 0.93; NNTB 8), but no difference in efficacy was found between valproate and lithium (RR 1.02, 95% CI 0.87 to 1.20). Valproate was associated with fewer participants dropping out of treatment for any cause when compared with placebo or lithium (RR 0.82, 95% CI 0.71 to 0.95 and RR 0.87, 95% CI 0.77 to 0.98, respectively). However, combination therapy with lithium plus valproate was more likely to prevent relapse than was monotherapy with valproate (RR 0.78, 95% CI 0.63 to 0.96). Significant differences in adverse event frequencies were found, and lithium was associated with more frequent diarrhoea, polyuria, increased thirst and enuresis, whereas valproate was associated with increased sedation and infection.

#### Authors' conclusions

Limited evidence supports the efficacy of valproate in the long-term treatment of bipolar disorder. Clinicians and patients should consider acceptability and tolerability profile when choosing between lithium and valproate-their combination or other agents-as long-term treatment for bipolar disorder.

#### PLAIN LANGUAGE SUMMARY

#### Valproate for keeping people with bipolar disorder well, after mood episodes

Bipolar disorder is a common and important disorder that includes episodes of depression, mixed states or mania. Depression includes low mood and energy, as well as lack of enjoyment, often combined with other problems such as sleep disturbance. Mania includes the opposite, with 'too much' energy and problems with high mood or irritation. In mixed states, the symptoms of depression and mania are combined. These mood episodes usually happen several times in an individual's life, so long-term treatment (maintenance treatment) can be very important in preventing relapse and recurrence. As valproate is a drug that may be useful in treating the acute

Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.





# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

